Chinese Biopharma Firms Achieve Multiple Breakthroughs in CAR-T Therapies, Poised to Capture Nearly $100 Billion Market

　　【Pharmaceutical Network Industry Dynamics】CAR-T is an innovative treatment method that has emerged in recent years. Simply put, it involves using bioengineering techniques to express artificially designed CAR molecules on T lymphocytes, creating CAR-T cells that are infused into the patient’s body to recognize specific antigens and eliminate target cells, thereby achieving the goal of treating or alleviating the disease. Recently, there have been multiple pieces of good news in the CAR-T field.
 

On January 11, 2025, the allogeneic universal CAR-T cell injection targeting CD19 (UC101) independently developed by UCELLO (referred to as "UCELLO") passed the application for a new drug clinical trial (IND) by the U.S. Food and Drug Administration (FDA) and was approved to carry out clinical trials.
 

Data shows that UC101 is the first indication product developed on UCELLO's umbilical cord blood allogeneic universal CAR-T technology platform, and will be used to conduct clinical trials for the treatment of acute B lymphoblastic leukemia. Its significance lies in demonstrating that the key process route for umbilical cord blood allogeneic universal CAR-T has gained recognition from international regulatory authorities, laying a solid foundation for subsequent IND applications for more targets and indications. In the future, UCELLO will also focus on developing treatments for more autoimmune diseases, including multiple myeloma, lymphoma, systemic lupus erythematosus, and Sjögren's syndrome.
 

It is reported that UC101 adopts a unique gene-editing combination, which can reduce immunogenicity, increase effectiveness, and better control adverse reactions. In this FDA IND application, the company successfully used imported umbilical cord blood from the United States to complete multiple batches of large-scale production in a GMP environment. One batch of production can supply more than 100 people, truly significantly reducing the cost of CAR-T cell therapy and improving medical accessibility.
 

In addition, CARsgen Therapeutics recently announced that KJ-C2219, a universal CAR-T cell therapy candidate product independently developed by the company targeting CD19/CD20, has completed the dosing of the first subject in an investigator-initiated clinical trial (IIT).
 

Data shows that KJ-C2219, developed based on the THANK-u Plus platform, is intended for the treatment of hematologic malignancies and autoimmune diseases. It is currently undergoing an investigator-initiated clinical trial in China targeting relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
 

It is reported that Carsgen Therapeutics focuses on innovative CAR-T cell therapies for treating hematologic malignancies and solid tumors. The company has established a CAR-T cell research and development platform covering target discovery, innovative CAR-T cell development, clinical trials, and commercial-scale production. By independently developing new technologies and owning a product pipeline with global rights, it aims to address major challenges faced by current CAR-T cell therapies, such as enhancing safety, improving efficacy in treating solid tumors, and reducing treatment costs.
 

The CAR-T market has broad prospects and is expected to approach 100 billion yuan. Data predicts that by 2032, the global CAR-T cell therapy market size is expected to reach $88.52 billion. Industry experts indicate that, similar to the PD-1 market, as more new products enter clinical trials and gradually come to market, along with the availability of various payment methods such as medical insurance, commercial insurance, and惠民保 (public welfare insurance), the price of CAR-T products in China is expected to gradually decrease, significantly improving their accessibility.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice for any person.